Zhao 2014b.

Methods	Study design: Randomised clinical trial Study duration: February 2007 to October 2010 Duration of follow‐up: 5 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by liver biopsy or images Exclusion criteria: With abnormal cardiac function; with serious mental diseases Age (mean ± SD): TACE + RFA: 57.3 ± 15.2 years; TACE alone: 56.5 ± 14.9 years Male (n/total): TACE + RFA: 22/40; TACE alone: 24/40
Interventions	TACE + RFA group (n = 40): TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g and theprubicin 20‐40 g RFA: CT‐guided RFA, 10 minutes per ablation session TACE group (n = 40): Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g and theprubicin 20‐40 g
Outcomes	Tumour necrosis, measured by CT 1‐, 3‐, and 5‐year survival rates Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.